Trial · NCT01259089
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) | Cohort 1 - 25 mg/m2 AUY922+75 mg Daily Erlotinib | 0 | Number of DLTs seen | ||
| Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) | Cohort 2 - 25 mg/m2AUY922+150 mg Daily Erlotinib | 0 | Number of DLTs seen | ||
| Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) | Cohort 3 - 37.5 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | Number of DLTs seen | ||
| Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) | Cohort 4 - 55 mg/m2 AUY922+150 mg Daily Erlotinib | 0 | Number of DLTs seen | ||
| Maximally Tolerated Dose (MTD) of AUY922 and Erlotinib Treatment Combination (Phase I) | Cohort 5 - 70 mg/m2 AUY922+150 mg Daily Erlotinib | 1 | Number of DLTs seen | ||
| Overall Response Rate (ORR), Defined as Complete Response(CR) + Partial Response (PR) Using the Modified RECIST 1.1 Criteria for All Patients Treated at Dose of 70mg/m2 AUG922 | Arm I | 4 | Participants | ||
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Diarrhea | 24 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Skin rash | 16 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Hyperglycemia | 23 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Night blindness | 18 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Hypoalbuminemia | 21 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Fatigue | 11 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Elevated AST | 17 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Nausea | 9 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Hyponatremia | 17 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Elevated bilirubin | 16 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Elevated ALT | 14 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Myalgias/arthralgias | 9 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Visual complaints | 10 | participants | |
| Toxicity as Assessed by NCI CTCAE Version 4.00 When AUG922 Administered at Its MTD (Phase I and II) | Arm I | Vomiting | 8 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01259089/results